A BILL 
To promote cannabis research, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Expanding Cannabis 
4
Research and Information Act’’. 
5
SEC. 2. CANNABIS RESEARCH AT THE DEPARTMENT OF 
6
HEALTH AND HUMAN SERVICES. 
7
(a) NATIONAL CANNABIS RESEARCH AGENDA.—Part 
8
B of title IV of the Public Health Service Act (42 U.S.C. 
9
23:16 Sep 13, 2019
H4322
2 
•HR 4322 IH
284 et seq.) is amended by adding at the end the fol-
1
lowing: 
2
‘‘SEC. 409K. NATIONAL CANNABIS RESEARCH AGENDA. 
3
‘‘Not later than 1 year after the date of enactment 
4
of the Expanding Cannabis Research and Information 
5
Act, the Director of NIH, in collaboration with the Direc-
6
tor of the Centers for Disease Control and Prevention and 
7
the Assistant Secretary for Mental Health and Substance 
8
Use, shall develop a national cannabis research agenda 
9
that addresses key questions and gaps in evidence, includ-
10
ing with respect to each of the following: 
11
‘‘(1) The efficacy of cannabis in providing 
12
therapeutic benefits for certain priority diseases or 
13
conditions, which may include epilepsy, multiple scle-
14
rosis-related spasticity, chemotherapy-induced pain 
15
and discomfort, using cannabis as an alternative to 
16
opioid analgesics for acute or chronic pain, sleep 
17
apnea, Tourette syndrome, anxiety, post-traumatic 
18
stress disorder, and any other disease or condition 
19
determined to be appropriate and of importance by 
20
the Director. 
21
‘‘(2) The effect of cannabis on at-risk popu-
22
lations, including children, older individuals, and 
23
pregnant or breast-feeding women. 
24
23:16 Sep 13, 2019
H4322
3 
•HR 4322 IH
‘‘(3) The long-term effects of cannabis use, in-
1
cluding dose-response relationship and the connec-
2
tion between cannabis use and behavioral health. 
3
‘‘(4) The clinically appropriate modes of deliv-
4
ery of cannabis. 
5
‘‘(5) Public safety considerations related to can-
6
nabis, including— 
7
‘‘(A) variation in the potency of cannabis 
8
products; 
9
‘‘(B) youth access to and use of cannabis, 
10
including marketing, packaging, edible formula-
11
tions, and flavor options that target youth; 
12
‘‘(C) risk factors for cannabis misuse; 
13
‘‘(D) impaired driving related to cannabis 
14
use; and 
15
‘‘(E) accidental ingestion of cannabis.’’. 
16
(b) SURVEILLANCE ACTIVITIES.—Part A of title III 
17
of the Public Health Service Act (42 U.S.C. 241 et seq.) 
18
is amended by adding at the end the following: 
19
‘‘SEC. 310B. SURVEILLANCE ACTIVITIES ON CANNABIS USE. 
20
‘‘(a) IN GENERAL.—The Secretary, acting through 
21
the Director of the Centers for Disease Control and Pre-
22
vention, in collaboration with the Assistant Secretary for 
23
Mental Health and Substance Use, the Administrator of 
24
the Centers for Medicare & Medicaid Services, and the Di-
25
23:16 Sep 13, 2019
H4322
4 
•HR 4322 IH
rector of the Agency for Healthcare Research and Quality, 
1
shall carry out surveillance activities to collect population- 
2
wide data on cannabis use. 
3
‘‘(b) PERMISSIBLE ACTIVITIES.— 
4
‘‘(1) IN GENERAL.—In carrying out activities 
5
under this section, the Secretary may collect, as ap-
6
propriate, with respect to cannabis use— 
7
‘‘(A) data on— 
8
‘‘(i) health outcomes, including bio-
9
logical data; 
10
‘‘(ii) health care utilization, which 
11
shall include hospitalizations and utiliza-
12
tion of emergency departments related to 
13
consumption of cannabis, including among 
14
youth; 
15
‘‘(iii) demographic factors associated 
16
with cannabis use; 
17
‘‘(iv) the variety of products and deliv-
18
ery modes used; and 
19
‘‘(v) other relevant health information 
20
to improve the understanding of cannabis 
21
use in all age groups and sub-populations; 
22
and 
23
‘‘(B) data through public health surveil-
24
lance systems, surveys, questionnaires, and 
25
23:16 Sep 13, 2019
H4322
5 
•HR 4322 IH
databases of health care records, including, as 
1
appropriate, the Behavioral Risk Factor Sur-
2
veillance System, the Youth Risk Behavioral 
3
Surveillance System, the Monitoring the Future 
4
health survey, the National Survey on Drug 
5
Use and Health, or the Healthcare Cost and 
6
Utilization Project (or any successor surveys). 
7
‘‘(2) PRIVACY.—Any data collected under para-
8
graph (1) shall be collected in manner that protects 
9
personal privacy to the extent, at a minimum, that 
10
is required under applicable Federal and State 
11
law.’’. 
12
SEC. 3. RESCHEDULING OF MARIHUANA. 
13
(a) IN GENERAL.—Subsection (c) of schedule I of 
14
section 202(c) of the Controlled Substances Act (21 
15
U.S.C. 812(c)) is amended by striking paragraph (10). 
16
(b) SCHEDULE III.—Schedule III of section 202(c) 
17
of the Controlled Substances Act (21 U.S.C. 812(c)) is 
18
amended by adding at the end the following: 
19
‘‘(f) Marihuana.’’. 
20
SEC. 4. CENTERS OF EXCELLENCE IN CANNABIS RE-
21
SEARCH. 
22
(a) IN GENERAL.—Part B of title IV of the Public 
23
Health Service Act (42 U.S.C. 284 et seq.), as amended 
24
23:16 Sep 13, 2019
H4322
6 
•HR 4322 IH
by section 2(a), is further amended by adding at the end 
1
the following: 
2
‘‘SEC. 409L. CENTERS OF EXCELLENCE IN CANNABIS RE-
3
SEARCH. 
4
‘‘(a) DESIGNATION.— 
5
‘‘(1) IN GENERAL.—The Director of NIH shall 
6
designate institutions of higher education as Centers 
7
of Excellence in Cannabis Research for the purpose 
8
of interdisciplinary research related to cannabis and 
9
other biomedical, behavioral, and social issues re-
10
lated to cannabis. No institution of higher education 
11
may be designated as a Center unless an application 
12
therefor has been submitted to, and approved by, the 
13
Director of NIH. Such an application shall be sub-
14
mitted in such manner and contain such information 
15
as the Director of NIH may reasonably require. The 
16
Director of NIH may not approve such an applica-
17
tion unless— 
18
‘‘(A) the application contains or is sup-
19
ported by reasonable assurances that— 
20
‘‘(i) at least 1 individual employed by 
21
the applicant— 
22
‘‘(I) is registered under section 
23
303(f) of the Controlled Substances 
24
Act to conduct research with con-
25
23:16 Sep 13, 2019
H4322
7 
•HR 4322 IH
trolled substances in schedule III of 
1
section 202(c) of that Act; and 
2
‘‘(II) is an active participant in 
3
the cannabis research activities of the 
4
applicant; 
5
‘‘(ii) the applicant has not had a reg-
6
istration to conduct research with con-
7
trolled substances under section 303 of the 
8
Controlled Substances Act denied, revoked, 
9
or suspended under section 304 of that 
10
Act; 
11
‘‘(iii) the applicant has the experience, 
12
or capability, to conduct, through bio-
13
medical, behavioral, social, and related dis-
14
ciplines, long-term research on cannabis 
15
and to provide coordination of such re-
16
search among such disciplines; 
17
‘‘(iv) the applicant has available to it 
18
sufficient personnel and facilities (includ-
19
ing laboratory, reference, storage, security, 
20
and data analysis facilities) to carry out 
21
the research plan required under subpara-
22
graph (B); and 
23
‘‘(v) the applicant has the capacity to 
24
conduct academic courses and train stu-
25
23:16 Sep 13, 2019
H4322
8 
•HR 4322 IH
dents and professionals on appropriate re-
1
search and knowledge of cannabis; and 
2
‘‘(B) the application contains a detailed 5- 
3
year plan for research relating to cannabis. 
4
‘‘(2) GEOGRAPHIC REPRESENTATION.—The Di-
5
rector of NIH shall ensure geographic representation 
6
across the United States in designating institutions 
7
of higher education as Centers of Excellence in Can-
8
nabis Research. 
9
‘‘(3) TERM
OF
DESIGNATION.—A designation 
10
under this section shall be for a period of 5 years. 
11
An institution of higher education may reapply in 
12
accordance with the requirements under paragraph 
13
(1) for a subsequent designation under this section. 
14
‘‘(b) CANNABIS RESEARCH.— 
15
‘‘(1) 
GRANTS
OR
COOPERATIVE
AGREE-
16
MENTS.— 
17
‘‘(A) IN GENERAL.—The Director of NIH 
18
may make grants to, or enter into cooperative 
19
agreements with, Centers that have been des-
20
ignated under this section to expand the cur-
21
rent and ongoing interdisciplinary research and 
22
clinical trials relating to cannabis research. 
23
‘‘(B) USE
OF
FUNDS.—Amounts made 
24
available under a grant or cooperative agree-
25
23:16 Sep 13, 2019
H4322
9 
•HR 4322 IH
ment under subparagraph (A) may be used to 
1
address key questions and gaps in evidence ad-
2
dressed by the national cannabis research agen-
3
da described in paragraphs (1) through (5) of 
4
section 409K. 
5
‘‘(2) RESEARCH
RESULTS.—The Director of 
6
NIH shall promptly disseminate research results 
7
under this subsection to relevant governmental, aca-
8
demic, and research entities. 
9
‘‘(c) DEFINITIONS.—In this section: 
10
‘‘(1) CANNABIS.—The term ‘cannabis’ has the 
11
meaning given the term ‘marihuana’ in section 102 
12
of the Controlled Substances Act. 
13
‘‘(2) INSTITUTION OF HIGHER EDUCATION.— 
14
The term ‘institution of higher education’ has the 
15
meaning given the term in section 101(a) of the 
16
Higher Education Act of 1965.’’. 
17
(b) REGISTRATION REQUIREMENTS.—Section 303(f) 
18
of the Controlled Substances Act (21 U.S.C. 823(f)) is 
19
amended by adding after the period at the end the fol-
20
lowing: ‘‘The Attorney General shall register under this 
21
part practitioners at Centers of Excellence in Cannabis 
22
Research designated under section 409L of the Public 
23
Health Service Act to conduct research with marihuana. 
24
No separate registration shall be required for each indi-
25
23:16 Sep 13, 2019
H4322
10 
•HR 4322 IH
vidual employed by a Center of Excellence in Cannabis Re-
1
search who is conducting research described in subsection 
2
(a)(1) of that section and in accordance with applicable 
3
State and local laws, nor shall separate registrations be 
4
required for distinct research activities, including research 
5
activities related to distinct constituent compounds of 
6
marihuana or amended protocols. The registration shall 
7
expire on the date on which the entity is no longer des-
8
ignated as such a Center of Excellence in Cannabis Re-
9
search under that section. A Center of Excellence in Can-
10
nabis Research registered under this part may cultivate 
11
marihuana, including any constituent component of mari-
12
huana, to conduct research under this part if the Attorney 
13
General has determined that the research to be conducted 
14
is for legitimate scientific research and is consistent with 
15
effective controls against diversion. A Center of Excellence 
16
in Cannabis Research may contract with such additional 
17
manufacturers of marihuana registered under this section 
18
to meet the needs of the Center of Excellence in Cannabis 
19
Research to the maximum extent permissible under inter-
20
national treaties to which the United States is a signatory 
21
and which govern marihuana. Before entering into such 
22
contract, the Center of Excellence in Cannabis Research 
23
shall submit to the Attorney General a request to enter 
24
into the contract that includes information to demonstrate 
25
23:16 Sep 13, 2019
H4322
11 
•HR 4322 IH
the experience or capability of the contractor to conduct 
1
such cultivation and assurances that the contractor will 
2
comply with the provisions of this Act. Not later than 60 
3
days after the date on which the request is submitted, the 
4
request shall be deemed to be approved by the Attorney 
5
General, unless the Attorney General determines that the 
6
granting of such request is inconsistent with the public 
7
interest. A Center of Excellence in Cannabis Research reg-
8
istered under this section may purchase or acquire com-
9
mercially available marihuana for the purpose of research 
10
described in section 409L(a)(1) of the Public Health Serv-
11
ice Act in accordance with the law of the State in which 
12
the transaction occurs. No Federal funds may be used by 
13
the Center of Excellence in Cannabis Research for such 
14
purchase or acquisition.’’. 
15
Æ 
23:16 Sep 13, 2019
H4322
